Plasma soluble interleukin‐2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome

Abstract

To assess the hypothesis that the plasma soluble interleukin-2 receptor (sIL-2R) level may have predictive value for morbidity/mortality in patients with myelodysplastic syndromes (MDS), we determined in plasma sIL-2R level of 80 MDS patients and examined their subsequent clinical course. Compared with low-risk MDS (refractory anaemia (RA) and RA with ringed sideroblasts) patients and normal subjects, the plasma sIL-2R level was significantly elevated in high-risk MDS (three other MDS subtypes and acute leukaemia following MDS) patients (high-risk MDS versus low-risk MDS, P < 0.01; high-risk MDS versus normal subjects, P < 0.01). 14/40 low-risk MDS patients developed at least one of the following during the follow-up period: erythrocyte transfusion dependence, infections requiring hospitalization, disease progression or MDS-related death. The plasma sIL-2R level was higher in these eventful subjects than in event-free low-risk subjects (P < 0.0001), and all of 10 low-risk subjects with a plasma sIL-2R level > 540 U/ml experience at least one event. By logistic regression analysis of various parameters in these 40 low-risk subjects, the plasma sIL-2R level was identified as the strongest independent parameter for predicting eventful subjects (P < 0.0047). The plasma sIL-2R level did not show a predictive value in high-risk MDS. This study revealed that the plasma sIL-2R level is significantly elevated in high-risk MDS and suggested that the plasma sIL-2R level is a valuable predictive factors for the clinical outcome in low-risk MDS.

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

“…At the present time, it is important to ensure that these analyses can be performed quickly and easily. Serum sIL-2R levels have been clinically investigated in a variety of human diseases such as myelodysplastic syndrome (Ogata et al 1996), Hodgkin's disease (Viviani et al 1998), B-chronic lymphocytic leukemia (Semenzato et al 1987), lymphoblastic lymphoma (Wagner et al 1987), and adult T-cell leukemia/lymphoma (Yasuda et al 1988). However, unexpectedly, there have been few prospective studies that have evaluated the prognostic significance of serum sIL-2R in adult aggressive NHL patients (Niitsu et al 2001;Kono et al 2000).…”

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

“…It has been demonstrated that IL-2R is released from the cell surface in a soluble form (sIL-2R) under particular conditions in vitro and in vivo (Rubin et al 1985). High serum levels of sIL-2R have been demonstrated in several diseases (Rubin et al 1985;Ogata et al 1996;Wasik et al 1996). The sIL-2R molecules can bind to IL-2, although it is not known whether malignant or normal activated T cells produce sIL-2R, both cell types have the capacity to release sIL-2R into the serum.…”

Coagulation, Fibrinolysis and Angiogenesis: New Insights from Knockout Mice

“…In fact, it has been appreciated that effects of uPA on cell migration are independent of urokinase’s catalytic activity; it has been demonstrated that uPA fragments containing only the receptor-binding domain are able to stimulate cell migration [25]. The role of uPA interaction with its cognate receptor, uPAR, in cell migration is further emphasized by the fact that uPAR-deficient neutrophils in patients with paroxysmal nocturnal hemoglobinuria are chemotaxis-defective [26]. The emerging paradigm of plasmin-independent action of urokinase ascribes to uPA-uPAR complex an important role in cell migration, binding to vitronectin and α V β 3 or β 1 integrin receptors [33].…”